CO7151500A2 - Preparación inyectable - Google Patents

Preparación inyectable

Info

Publication number
CO7151500A2
CO7151500A2 CO14256422A CO14256422A CO7151500A2 CO 7151500 A2 CO7151500 A2 CO 7151500A2 CO 14256422 A CO14256422 A CO 14256422A CO 14256422 A CO14256422 A CO 14256422A CO 7151500 A2 CO7151500 A2 CO 7151500A2
Authority
CO
Colombia
Prior art keywords
injectable preparation
present
viscosity
composition
dispersion medium
Prior art date
Application number
CO14256422A
Other languages
English (en)
Inventor
Daiki Kaneko
Takakuni Matsuda
Yusuke Hoshika
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7151500(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CO7151500A2 publication Critical patent/CO7151500A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un objeto de la presente invención es brindar unapreparación inyectable estable durante el almacenamientoque comprende una composición que comprende un fármacopoco soluble como ingrediente activo, y que ademáscomprende un medio de dispersión. Otro objeto de lapresente invención es brindar una jeringa prellenadacompacta, liviana mediante el prellenado de la jeringacon la preparación inyectable. La presente invenciónbrinda una preparación inyectable que comprende unacomposición que comprende un fármaco poco soluble, unmedio de dispersión y un agente de suspensión específicoque tiene una viscosidad de 40 Pa·s o más en, al menos,un punto en el rango de velocidad de corte que oscilaentre 0,01 y 0,02 s-1 y tiene una viscosidad de 0,2 Pa·s oinferior, en al menos un punto en el rango de velocidadde corte que oscila entre 900 y 1,000 s-1, como se hamedido.
CO14256422A 2012-04-23 2014-11-21 Preparación inyectable CO7151500A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636938P 2012-04-23 2012-04-23
US201361792089P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CO7151500A2 true CO7151500A2 (es) 2014-12-29

Family

ID=48614096

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14256422A CO7151500A2 (es) 2012-04-23 2014-11-21 Preparación inyectable

Country Status (32)

Country Link
US (8) US20150093442A1 (es)
EP (2) EP2841054B2 (es)
JP (6) JP6234996B2 (es)
KR (4) KR20210116702A (es)
CN (3) CN114344259B (es)
AR (1) AR090776A1 (es)
AU (5) AU2013253374B2 (es)
BR (1) BR112014026307B1 (es)
CA (2) CA2869889C (es)
CO (1) CO7151500A2 (es)
CY (1) CY1122252T1 (es)
DK (1) DK2841054T4 (es)
EA (1) EA026619B1 (es)
ES (1) ES2743706T5 (es)
HK (2) HK1206988A1 (es)
HR (1) HRP20191366T4 (es)
HU (1) HUE045979T2 (es)
IL (1) IL235299B (es)
JO (2) JOP20200109A1 (es)
LT (1) LT2841054T (es)
MX (1) MX359241B (es)
MY (2) MY198007A (es)
NZ (1) NZ630335A (es)
PH (2) PH12014502379B1 (es)
PL (1) PL2841054T5 (es)
PT (1) PT2841054T (es)
SG (3) SG10201608753UA (es)
SI (1) SI2841054T2 (es)
TW (4) TW202126303A (es)
UA (1) UA115444C2 (es)
WO (1) WO2013162048A1 (es)
ZA (1) ZA201407335B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
CN110198742B (zh) * 2017-01-26 2021-11-30 四川瀛瑞医药科技有限公司 一种纳米炭-铁复合体系及其组合物、制备方法和用途
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
US20210401775A1 (en) * 2018-11-02 2021-12-30 Amaterasu Lifesciences Llp A liquid injectable composition
WO2021199076A1 (en) * 2020-03-30 2021-10-07 Cipla Limited Injectable aripiprazole formulation
TW202200141A (zh) * 2020-04-01 2022-01-01 日商大塚製藥股份有限公司 阿立哌唑治療之劑量起始方法
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11910794B2 (en) * 2021-03-08 2024-02-27 Monsanto Technology Llc Solutions and methods for long-term pollen storage
WO2023067664A1 (ja) * 2021-10-18 2023-04-27 大塚製薬株式会社 ベンゾチオフェン化合物の新規結晶形及びその製造方法
CN117529309A (zh) * 2022-06-16 2024-02-06 江苏慧聚药业股份有限公司 药物组合物及依匹哌唑口溶膜

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864100A (en) * 1957-04-09 1961-03-29 Pfizer & Co C Therapeutic pencillin compositions and the preparation thereof
JPS5913714A (ja) 1982-07-13 1984-01-24 Taito Pfizer Kk 外用消炎鎮痛剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
MY138669A (en) * 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003171264A (ja) * 2001-12-07 2003-06-17 Taiyo Yakuhin Kogyo Kk マイクロカプセル及びその製造方法
JP2003238393A (ja) 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
WO2004017897A2 (en) 2002-08-20 2004-03-04 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
ATE376419T1 (de) 2002-12-27 2007-11-15 Otsuka Pharma Co Ltd Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
KR100583667B1 (ko) 2003-01-09 2006-05-26 오쓰까 세이야꾸 가부시키가이샤 아리피프라졸의 제조방법
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20070110784A1 (en) * 2003-05-02 2007-05-17 Rimon Therapeutics Ltd. Thermally reversible implant
WO2004105682A2 (en) 2003-05-23 2004-12-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
ATE424816T1 (de) 2003-10-27 2009-03-15 Dow Corning Zubereitungen für die topische anwendung und verfahren zur abgabe eines wirkstoffs an ein substrat
WO2005070332A1 (en) 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
JP2006219380A (ja) * 2005-02-08 2006-08-24 Minofuaagen Seiyaku:Kk グリチルリチン皮下注射製剤
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
CN101309713A (zh) 2005-11-17 2008-11-19 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
JP4373983B2 (ja) 2006-01-27 2009-11-25 三菱電機インフォメーションシステムズ株式会社 流通経路管理装置及び流通経路管理プログラム
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
JP2010505819A (ja) * 2006-10-05 2010-02-25 パナセア バイオテック リミテッド デポ型注射剤組成物とその調製方法
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
US20100151459A1 (en) 2007-01-26 2010-06-17 Jun Soo Kwon Marker for detecting the proposed efficacy of treatment
UA96342C2 (en) 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
UA97286C2 (ru) 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2009286740A (ja) 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
TR200809200A1 (tr) 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
EP2435027B1 (en) 2009-05-27 2016-10-05 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
UA108862C2 (uk) 2009-09-11 2015-06-25 Терапевтичний агент проти хронічного болю
MY174552A (en) * 2010-08-24 2020-04-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
JP2012121850A (ja) 2010-12-09 2012-06-28 Otsuka Pharmaceut Co Ltd アリピプラゾールの経口速溶性組成物
AU2012209853B2 (en) 2011-01-24 2016-06-16 Otsuka Pharmaceutical Co., Ltd. Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
AR085840A1 (es) 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
JP2012232958A (ja) † 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US9241876B2 (en) 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
RU2601420C2 (ru) 2011-07-28 2016-11-10 Оцука Фармасьютикал Ко., Лтд. СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ БЕНЗО[b]ТИОФЕНА
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JO3190B1 (ar) 2011-10-19 2018-03-08 Otsuka Pharma Co Ltd محلول للتناول عن طريق الفم
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JP2013139441A (ja) 2011-12-28 2013-07-18 Otsuka Pharmaceut Co Ltd マイクロスフェア
AR090245A1 (es) 2012-03-06 2014-10-29 Otsuka Pharma Co Ltd Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable

Also Published As

Publication number Publication date
PT2841054T (pt) 2019-09-09
TW202126303A (zh) 2021-07-16
DK2841054T3 (da) 2019-09-09
SI2841054T1 (sl) 2019-09-30
US12016927B2 (en) 2024-06-25
US20200179517A1 (en) 2020-06-11
US20210085794A1 (en) 2021-03-25
PH12014502379A1 (en) 2015-01-12
BR112014026307B1 (pt) 2022-10-11
CA2869889A1 (en) 2013-10-31
ES2743706T3 (es) 2020-02-20
AU2017228608B2 (en) 2018-10-18
MY198007A (en) 2023-07-25
CN104470499B (zh) 2018-03-16
JP2021008512A (ja) 2021-01-28
JP6234996B2 (ja) 2017-11-22
AU2017228608C1 (en) 2019-02-21
WO2013162048A1 (en) 2013-10-31
US20230390399A1 (en) 2023-12-07
EA201491685A1 (ru) 2015-04-30
JP6470378B2 (ja) 2019-02-13
CN108186556A (zh) 2018-06-22
AR090776A1 (es) 2014-12-03
MY178573A (en) 2020-10-16
JOP20200109A1 (ar) 2017-06-16
US11638757B2 (en) 2023-05-02
BR112014026307A2 (pt) 2017-06-27
CY1122252T1 (el) 2020-11-25
US11097007B2 (en) 2021-08-24
TWI637752B (zh) 2018-10-11
TW201350136A (zh) 2013-12-16
US20190099494A1 (en) 2019-04-04
KR20210116702A (ko) 2021-09-27
JO3632B1 (ar) 2020-08-27
SG10201913425VA (en) 2020-03-30
EP2841054B1 (en) 2019-06-26
CN104470499A (zh) 2015-03-25
KR20200064173A (ko) 2020-06-05
MX2014012811A (es) 2015-05-07
TW202313036A (zh) 2023-04-01
AU2019200060A1 (en) 2019-01-31
CN114344259A (zh) 2022-04-15
DK2841054T4 (da) 2022-06-13
SG11201406451SA (en) 2014-11-27
AU2022241491A1 (en) 2022-10-20
LT2841054T (lt) 2019-09-10
HRP20191366T1 (hr) 2019-12-27
JP2015514751A (ja) 2015-05-21
UA115444C2 (uk) 2017-11-10
AU2013253374B2 (en) 2017-06-15
HK1257028A1 (zh) 2019-10-11
EP2841054A1 (en) 2015-03-04
KR102498075B1 (ko) 2023-02-10
US10517951B2 (en) 2019-12-31
JP2018048179A (ja) 2018-03-29
JP2019070028A (ja) 2019-05-09
MX359241B (es) 2018-09-20
CA3120297A1 (en) 2013-10-31
KR20240068788A (ko) 2024-05-17
US20190336607A1 (en) 2019-11-07
HUE045979T2 (hu) 2020-01-28
US20180055941A1 (en) 2018-03-01
PL2841054T5 (pl) 2022-07-18
JP2023113806A (ja) 2023-08-16
PH12019500498A1 (en) 2020-03-02
PL2841054T3 (pl) 2019-10-31
AU2013253374A1 (en) 2014-10-23
AU2017228608A1 (en) 2017-10-05
CN108186556B (zh) 2022-06-10
JP7293412B2 (ja) 2023-06-19
TW201900174A (zh) 2019-01-01
EA026619B1 (ru) 2017-04-28
US20220096638A1 (en) 2022-03-31
SI2841054T2 (sl) 2022-05-31
HRP20191366T4 (hr) 2022-08-19
ZA201407335B (en) 2019-06-26
JP2022050619A (ja) 2022-03-30
CA2869889C (en) 2021-07-20
NZ630335A (en) 2016-07-29
IL235299A0 (en) 2014-12-31
KR20150003861A (ko) 2015-01-09
US20150093442A1 (en) 2015-04-02
AU2020204200A1 (en) 2020-07-16
ES2743706T5 (es) 2022-05-25
PH12014502379B1 (en) 2015-01-12
IL235299B (en) 2019-12-31
EP3539534A1 (en) 2019-09-18
TWI713826B (zh) 2020-12-21
EP2841054B2 (en) 2022-04-06
HK1206988A1 (en) 2016-01-22
AU2020204200B2 (en) 2022-06-30
SG10201608753UA (en) 2016-12-29
KR102138852B1 (ko) 2020-07-28
CN114344259B (zh) 2024-02-13

Similar Documents

Publication Publication Date Title
CO7151500A2 (es) Preparación inyectable
CY1117964T1 (el) Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
BR112013016770A2 (pt) formulação farmacêutica, fármaco biofarmacêutico, seringa ou caneta pré-preenchida, uso de uma formulação farmacêutica
CR20150174A (es) Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio
NZ630560A (en) Pharmaceutical compositions for combination therapy
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
BR112015008954A2 (pt) composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
PE20190210A1 (es) Aplicaciones de carrimicina en la infeccion por micobacterium tuberculosis resistente
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
AR084487A1 (es) Componente prostesico con una superficie deslizante que contiene un recubrimiento antimicrobiano
NZ603783A (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
GB201204632D0 (en) Delivery system
AR094203A1 (es) Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida
RS54362B1 (en) Intravenous infusion of IBUPROFEN
BR112019002058A2 (pt) composição injetável de ibuprofeno estável
TW202425992A (zh) 可注射製劑
PE20150022A1 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis